GMAB Genmab A/S - American Depositary Shares

NASDAQ · Biotechnology
$33.57
Price · Aug 19, 2026
52W Range
$24–$35
84% of range
Analyst Rating
BUY
26 analysts
Price Target
$39
+15% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—

GMAB Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

Price
$33.57
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$24 – $35

GMAB Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

10-Year Performance Revenue, net income, margins and EPS trends

Revenue & Net Income —
EPS —
Free Cash Flow —
Margins —

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric
5Y trend
GMAB
Peer Median

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric
5Y trend
GMAB
Peer Median

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric
5Y trend
GMAB
Peer Median

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric
5Y trend
GMAB
Peer Median

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric
5Y trend
GMAB
Peer Median

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric
5Y trend
GMAB
Peer Median

GMAB Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

BUY 26 analysts
  • Strong Buy 6 23.1%
  • Buy 15 57.7%
  • Hold 3 11.5%
  • Sell 1 3.8%
  • Strong Sell 1 3.8%

12-Month Price Target

10 analysts · 2026-08-13
Median target $40.00 +19.2%
Mean target $38.72 +15.3%

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Avg Surprise
0.14%
Period EPS Actual EPS Est Surprise
June 30, 2026 $4.91 $3.59 1.3%
March 31, 2026 $0.83 $1.41 -0.58%
Dec. 31, 2025 $2.13 $3.50 -1.4%
Sept. 30, 2025 $6.46 $4.74 1.7%
June 30, 2025 $5.42 $4.33 1.1%
March 31, 2025 $2.13 $3.50 -1.4%

Peer comparison (GICS sub-industry) Key metrics vs sector peers

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
GMAB — — — — — —
ASND — — — — — —
EVAX — — — — — —

GMAB AI Analyst Panel — Bullish and Bearish Views 2026Q2 debate: Claude, Grok, Gemini, ChatGPT on the stock's prospects

Round 1 — Opening Takes

Grok NEUTRAL 0.75
↑ Bullish

I see Genmab as a biotech cash machine with sky-high profitability that could drive outsized returns if their pipeline delivers. Their 27.6% ROE towers over peers, meaning they squeeze massive profits from every dollar of shareholder equity in a sector where losses are common. Net margins hit 41.4%, proving they convert nearly half of sales to bottom-line profit thanks to royalty streams and low costs. At a 13.3 P/E, the stock trades like a value play despite earnings doubling recently, leaving room for multiple expansion into 2026.

↓ Bearish

My worry is Genmab's high returns look fragile if drug approvals stall or competition erodes their edge. Debt-to-equity at 2.5 signals leverage that amplifies risks in biotech's lumpiness, where one trial flop could tank equity. Recent price action shows a 7% drop from June highs around $23 to $21.4, with volume spikes hinting at selling pressure. That P/E compression from 82 to 13 reflects market doubts on sustaining 94% gross margins amid patent cliffs.

Claude NEUTRAL 0.62
↑ Bullish

Genmab is printing cash with the profitability of a mature software company, not a biotech. My read is the market has finally woken up to the quality of the earnings here. Net margin sits at 41.35%, which for a company dependent on drug manufacturing and distribution is almost unheard of — that tells me either the portfolio is genuinely differentiated or the cost structure is locked in. ROE of 27.6% compounds capital efficiently. The P/E of 13.25 looks absurdly cheap for a company growing EPS and holding gross margins above 94%. If the pipeline holds and one major drug doesn't crater, this re-rates higher.

↓ Bearish

I'm watching a company that looks cheap on paper but may be a value trap if you dig into the debt. The D/E ratio is 2.47, which means Genmab is leveraged — that 27.6% ROE is partly a function of borrowed money, not pure operational excellence. More concerning: Q3 2025 shows the company was trading at a 82.2 P/E with EPS of only 17.67, then suddenly Q1 2026 shows a 13.25 P/E with the same EPS of 23.50. That's not a rebound — that's either an accounting restatement or a data anomaly I don't trust. Until I see clean quarters, I'm skeptical this margin profile holds.

Gemini NEUTRAL 0.75
↑ Bullish

Genmab is currently a profit-generating machine that has successfully transitioned from a speculative biotech into a highly efficient pharmaceutical powerhouse. The company is delivering a 41.35% net profit margin. This indicates that for every dollar of revenue, they are keeping over 40 cents as pure profit, which is a rare level of efficiency in drug development. Furthermore, with a current ratio of 6.03, they have massive short-term liquidity. This means they can fund their own R&D pipeline and potential acquisitions for years without needing to tap the volatile capital markets for cash.

↓ Bearish

My primary concern is that the market may have already priced in the best of the growth, leaving little room for error if their pipeline hits a snag. The stock is trading at a P/E of 13.25. While that looks cheap on the surface, it suggests investors are skeptical about the sustainability of their current earnings trajectory. Additionally, the debt-to-equity ratio sits at 2.47. This level of leverage means that if their drug sales growth slows down, the interest burden could quickly become a significant drag on their bottom line.

Chatgpt NEUTRAL 0.62
↑ Bullish

Claude, I think Genmab's bullish case rests on durable profitability and strong capital efficiency. ROE TTM: 27.64%. That shows the company converts equity into profits efficiently, supporting a higher earnings trajectory into 2026. Gross margin TTM: 94.27%. That signals premium pricing and a robust product mix, giving Genmab a wide moat to protect margins. EPS TTM: 23.50. That level of profitability underpins cash flow generation and optionality for buybacks or dividends.

↓ Bearish

GROK, my bear case is that Genmab's high leverage could bite if growth slows. Debt/Equity: 2.47. That high leverage magnifies downside risk if earnings deteriorate or rates rise, and it can constrain future capital allocation in a tougher cycle. P/E TTM: 13.25. Valuation looks fair but leaves little cushion for disappointment if the pipeline underperforms, since any setback would likely compress the multiple. P/B Annual: 3.04. A valuation built on intangible assets can re-rate quickly if fundamentals falter, especially if competitive dynamics shift.

Round 2 — Responses & Rebuttals

Grok

Claude, your skepticism on the P/E drop as an anomaly overlooks the EPS growth behind it. EPS TTM rose from 17.67 in Q3 2025 to 23.50 now, a 33% jump that directly compresses the multiple from 82 to 13 alongside market cap growth. That signals genuine profit acceleration turning biotech lumpiness into reliable earnings power, not accounting tricks — strengthening the buy case for 2026.

Claude

I need to push back on Grok here — that P/E compression from 82 to 13 isn't evidence of market doubt, it's a sign the earnings base shifted dramatically. Q3 2025 shows EPS of 17.67; Q1 2026 shows 23.50. That's a 33% jump in trailing earnings, not a multiple collapse. When your denominator grows that fast, the ratio compresses naturally. Grok is reading the math backwards — the market isn't skeptical, it's repricing on better fundamentals. The real question is whether that 23.50 EPS holds or reverts, not whether the P/E looks cheap relative to a quarter where earnings were artificially depressed.

Gemini ⇄ Mind changed

Claude, your skepticism regarding the P/E compression from 82 to 13 is the most important point on the table today. That massive drop in the trailing multiple suggests the market is pricing in a 'peak earnings' scenario rather than sustainable growth. If the market truly believed those 41.35% net margins were permanent, the stock would be trading at a much higher premium. This means investors are essentially betting that the current profitability is a temporary windfall, and I am leaning toward agreeing with your cautious outlook on their valuation.

Chatgpt

Claude, my read is that the debt load is valid and deserves closer scrutiny. Genmab's debt-to-equity ratio of 2.47 is a lever that could bite if earnings slow, because interest costs would compress profits more than in a cash-rich peer. Still, the business earnings power and pipeline resilience give it insulation to ride through volatility, so the leverage is not an automatic red flag if execution holds. If growth stalls, however, the leverage remains the main risk to the downside.

Round 3 — Final Rebuttals

G
Grok

Gemini, your claim that the P/E drop signals a peak earnings scenario misses how real profit growth drove it. EPS TTM jumped 33% from 17.67 in Q3 2025 to 23.50 now, while market cap rose from 93 billion to 125 billion — that's the market rewarding acceleration, not capping it at a peak. With gross margins steady at 94%, this points to sustainable biotech efficiency, bolstering my buy for 2026 upside if the pipeline advances.

C
Claude

I want to push back on something ChatGPT said that nobody touched: the idea that Genmab's leverage is 'not an automatic red flag if execution holds.' That's doing a lot of work. A 2.47 debt-to-equity ratio means for every dollar of equity, they owe 2.47 dollars — that's not moderate leverage in biotech, that's aggressive. The real issue isn't whether the business can service it today; it's that biotech cash flows are lumpy. One failed Phase 3 trial, one patent cliff, and that interest burden becomes a vise. ChatGPT is right that the pipeline matters, but I'd flip it: the leverage doesn't get a pass just because fundamentals are solid now. It's exactly the thing that turns a stumble into a crater.

G
Gemini

I am widening the frame to address the institutional positioning that both Claude and Grok are missing. The stock’s recent volume profile, with over 12 million shares traded in late June, suggests heavy institutional distribution rather than simple retail volatility. This is a classic sign of 'smart money' exiting ahead of the upcoming patent expiration for Darzalex, their primary revenue driver. When a company relies on a single blockbuster drug for the bulk of its cash flow, that 41.35% net margin is not a permanent feature of the business, but a temporary peak that institutional investors are actively selling into.

C
Chatgpt

I think, Claude, your assertion that P/E compression isn't evidence of market doubt misses a critical signal about investor psychology and the sustainability of Genmab's current earnings trajectory. The trailing P/E has collapsed from roughly 82x to about 13x. That magnitude of re-rating typically implies investors doubt whether the current profits are sustainable, especially when the bar has been reset so abruptly after a strong quarter.

Price Forecasts

Model 3M Target 6M Target Reasoning
G Grok 3M Target $24.00 6M Target $28.00 Reasoning I see Genmab's rare biotech profitability trading at a discount, setting up multiple expansion toward 2026Q2 if earnings hold. The concrete catalyst is Q2 2026 earnings in late July, where pipeline progress on epcoritamab could confirm EPS sustainability and ignite buying. The key risk is Darzalex biosimilar competition eroding royalties before 2030. At 13.25 P/E, the market pays little for 41% net margins that signal moat-like efficiency, so a re-rating to 18x justifies $24 in 3 months and $28 in 6 on steady growth.
C Claude 3M Target $22.50 6M Target $24.75 Reasoning Genmab's 41% net margin and 27.6% ROE are real, but they rest on a fragile foundation: Darzalex concentration and 2.47 debt-to-equity leverage. My thesis is the stock re-rates modestly higher if Q2 2026 earnings hold flat or grow, but any stumble triggers a sharp multiple compression. Catalyst: Q2 2026 earnings in late July—if EPS stays above 23, the market grants a 15–18 P/E multiple, pushing the stock to 24–26. Risk: Darzalex patent cliff acceleration or a pipeline setback compresses the multiple back to 11–12, cratering the stock to 18. At 13.25 P/E today, the market is already pricing skepticism; I'm betting on execution, not expansion. Three-month target assumes modest consolidation; six-month assumes one clean earnings print justifies a slight multiple lift.
G Gemini 3M Target $19.50 6M Target $18.00 Reasoning My thesis is that Genmab is facing a valuation reset as the market discounts the sustainability of its current earnings peak. The primary catalyst for a downside move will be the upcoming Q3 2026 earnings report, where I expect investors to scrutinize the revenue contribution from Darzalex as patent expiration pressure mounts. Conversely, a failure to maintain their 41.35% net margin would be the specific risk that shatters the current bullish narrative. The stock is currently trading at a P/E of 13.25, which, while appearing cheap, reflects a market that is increasingly skeptical about the long-term durability of these profits compared to the company's high debt load.
C Chatgpt 3M Target $22.00 6M Target $24.00 Reasoning Genmab still offers modest upside into 2026 mid-year on durable profitability, but leverage and pipeline risk cap upside. A Q2 2026 earnings print showing sustained EPS growth and strong margins would push the stock toward the 6-month target. If Darzalex revenue stalls or a key trial falters, the leverage becomes a bigger headwind and could break the thesis. From about $20.60 today, my 3-month target is $22, and my 6-month target is $24, implying roughly 7% and 16% upside.

Trading Signals Recent buy/sell signals with entry price and risk/reward ratio

My Metrics Your personal watchlist — selected rows from Full Fundamentals

📊

Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Institutional owners (13F) 321 filers · $2.6B total · As of June 30, 2026

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
55 (+7 vs prior Q) 30 (-25 vs prior Q) 102 (-2 vs prior Q) 94 (+4 vs prior Q) +35.5M

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
Paradigm Biocapital Advisors LP $360,767,109 13,133,131 13.94% Shares
Orbis Allan Gray Ltd $311,366,077 11,334,768 12.03% Shares
ALLIANCEBERNSTEIN L.P. $231,942,050 8,644,877 8.96% Shares
DEERFIELD MANAGEMENT COMPANY, L.P. $188,581,550 6,865,000 7.29% Shares
Deep Track Capital, LP $155,205,500 5,650,000 6.00% Shares
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP $136,672,150 4,975,324 5.28% Shares
Sofinnova Investments, Inc. $111,122,056 4,045,215 4.29% Shares
RENAISSANCE TECHNOLOGIES LLC $96,635,340 3,517,850 3.73% Shares
TWO SIGMA INVESTMENTS, LP $96,332,977 3,506,843 3.72% Shares
Harding Loevner LP $86,898,395 3,086,318 3.36% Shares
Deep Track Capital, LP $82,410,000 3,000,000 3.18% Call option
FIRST TRUST ADVISORS LP $75,721,659 2,756,522 2.93% Shares
CITADEL ADVISORS LLC $52,715,562 1,919,023 2.04% Shares
Qube Research & Technologies Ltd $46,404,631 1,689,284 1.79% Shares
FRANKLIN RESOURCES INC $32,203,218 1,172,305 1.24% Shares
MORGAN STANLEY $32,133,656 1,169,772 1.24% Shares
Brandywine Global Investment Management, LLC $31,769,091 1,031,464 1.23% Shares
Pictet Asset Management Holding SA $29,281,015 1,065,927 1.13% Shares
MILLENNIUM MANAGEMENT LLC $25,014,292 910,604 0.97% Shares
Perpetual Ltd $23,937,248 871,396 0.93% Shares
ENVESTNET ASSET MANAGEMENT INC $22,791,195 829,687 0.88% Shares
Alyeska Investment Group, L.P. $22,096,154 804,374 0.85% Shares
Caption Management, LLC $19,174,060 698,000 0.74% Call option
AMERICAN CENTURY COMPANIES INC $16,480,709 599,953 0.64% Shares
CIBC WORLD MARKET INC. $14,140,567 514,764 0.55% Shares
GOLDMAN SACHS GROUP INC $12,525,386 455,966 0.48% Shares
SUPERSTRING CAPITAL MANAGEMENT LP $11,828,582 430,600 0.46% Shares
MOORE CAPITAL MANAGEMENT, LP $11,550,778 420,487 0.45% Shares
Dixon Mitchell Investment Counsel Inc. $11,427,520 416,000 0.44% Shares
TWO SIGMA ADVISERS, LP $10,472,000 340,000 0.40% Shares
Quantinno Capital Management LP $9,158,195 333,388 0.35% Shares
Hudson Bay Capital Management LP $9,065,100 330,000 0.35% Shares
SummitTX Capital, L.P. $8,746,668 318,408 0.34% Shares
CITADEL ADVISORS LLC $8,578,881 312,300 0.33% Call option
EAGLE GLOBAL ADVISORS LLC $6,722,733 244,730 0.26% Shares
ASSETMARK, INC $6,559,918 238,803 0.25% Shares
JANE STREET GROUP, LLC $6,518,631 237,300 0.25% Call option
NORTHERN TRUST CORP $6,282,114 228,690 0.24% Shares
BNP PARIBAS FINANCIAL MARKETS $6,262,885 227,990 0.24% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $6,081,858 221,400 0.24% Call option
Caption Management, LLC $5,487,792 199,774 0.21% Shares
FOLKETRYGDFONDET $4,534,803 165,082 0.18% Shares
AIMZ Investment Advisors, LLC $4,420,198 160,910 0.17% Shares
JANE STREET GROUP, LLC $4,229,309 153,961 0.16% Shares
LPL Financial LLC $3,964,507 144,321 0.15% Shares
Schonfeld Strategic Advisors LLC $3,882,965 141,353 0.15% Shares
Balyasny Asset Management L.P. $3,876,017 141,100 0.15% Call option
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $3,821,764 139,125 0.15% Shares
Point72 Asset Management, L.P. $3,726,223 135,647 0.14% Shares
Woodline Partners LP $3,664,141 133,387 0.14% Shares
Point72 Europe (London) LLP $3,308,169 107,864 0.13% Shares
AQR CAPITAL MANAGEMENT LLC $2,885,822 105,054 0.11% Shares
Ishara Investments LP $2,815,675 102,500 0.11% Shares
Legacy Wealth Asset Management, LLC $2,806,445 102,164 0.11% Shares
BlackRock, Inc. $2,503,698 91,143 0.10% Shares
Integrated Quantitative Investments LLC $2,492,023 90,718 0.10% Shares
Quadrature Capital Ltd $2,158,290 78,569 0.08% Shares
Cetera Investment Advisers $2,100,191 76,454 0.08% Shares
US BANCORP \DE\ $2,044,400 74,423 0.08% Shares
QRG CAPITAL MANAGEMENT, INC. $1,995,505 72,643 0.08% Shares
OPPENHEIMER ASSET MANAGEMENT INC. $1,970,725 71,741 0.08% Shares
IMC-Chicago, LLC $1,966,742 71,596 0.08% Shares
Madison Asset Management, LLC $1,944,354 70,781 0.08% Shares
GEODE CAPITAL MANAGEMENT, LLC $1,805,081 65,711 0.07% Shares
Terra Nova Asset Management LLC $1,764,646 64,239 0.07% Shares
AMERIPRISE FINANCIAL INC $1,601,227 58,290 0.06% Shares
LEVEL FOUR ADVISORY SERVICES, LLC $1,593,260 58,000 0.06% Shares
MML INVESTORS SERVICES, LLC $1,536,892 55,948 0.06% Shares
Callan Family Office, LLC $1,511,756 55,033 0.06% Shares
Mariner, LLC $1,500,898 54,677 0.06% Shares
H D Vest Advisory Services $1,479,979 71,635 0.06% Shares
BANK OF AMERICA CORP /DE/ $1,397,042 50,857 0.05% Shares
Avidity Partners Management LP $1,373,500 50,000 0.05% Shares
Vanguard Personalized Indexing Management, LLC $1,360,067 49,511 0.05% Shares
Entropy Technologies, LP $1,336,525 48,654 0.05% Shares
DIMENSIONAL FUND ADVISORS LP $1,322,264 48,135 0.05% Shares
Pinnacle Financial Partners, Inc. $1,306,830 47,573 0.05% Shares
FIFTH THIRD BANCORP $1,296,062 47,181 0.05% Shares
RAYMOND JAMES FINANCIAL INC $1,258,703 45,821 0.05% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $1,249,885 45,500 0.05% Put option
BAROMETER CAPITAL MANAGEMENT INC. $1,247,138 45,400 0.05% Shares
CITADEL ADVISORS LLC $1,244,391 45,300 0.05% Put option
Walleye Capital LLC $1,216,921 44,300 0.05% Call option
ExodusPoint Capital Management, LP $1,185,935 43,172 0.05% Shares
Nuveen, LLC $1,179,772 42,948 0.05% Shares
DAVENPORT & Co LLC $1,168,691 42,544 0.05% Shares
LMR Partners LLP $1,159,124 42,196 0.04% Shares
WINTON GROUP Ltd $1,123,523 40,900 0.04% Shares
RHUMBLINE ADVISERS $1,098,372 39,985 0.04% Shares
SYNOVUS FINANCIAL CORP $1,069,064 34,857 0.04% Shares
GRANDFIELD & DODD, LLC $1,033,779 37,633 0.04% Shares
FMR LLC $1,023,699 37,266 0.04% Shares
Madison Investment Advisors, LLC $978,886 46,904 0.04% Shares
JANE STREET GROUP, LLC $961,450 35,000 0.04% Put option
Skopos Labs, Inc. $961,122 35,823 0.04% Shares
UBS Group AG $956,011 34,802 0.04% Shares
Cubist Systematic Strategies, LLC $895,302 29,191 0.03% Shares
GTS SECURITIES LLC $882,227 32,116 0.03% Shares
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $875,839 32,644 0.03% Shares
CAPITAL FUND MANAGEMENT S.A. $861,486 31,361 0.03% Shares

Company insiders 1 insider · 0 officers · 0 directors

Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Genmab A/S 10% owner Dec. 29, 2025 P 0 11 0 $7,593,976,255

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

Activists & 5%+ owners 1 position

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
Genmab A/S, Genmab Holding II B.V. ×2 filings Dec. 30, 2025 0.00% Amendment — SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

ETF ownership Held by 43 ETFs

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
EDEN · iShares Trust 4.35% 30,321 SH Aug. 8, 2026 Daily
IDNA · iShares Trust 4.11% 28,069 SH Aug. 8, 2026 Daily
CANC · Tema ETF Trust 2.37% 158,861 NS May 31, 2026 N-PORT
IBB · iShares Trust 1.20% 3,835,277 SH Aug. 8, 2026 Daily
SDG · iShares Trust 0.50% 3,011 SH Aug. 8, 2026 Daily
IXJ · iShares Trust 0.23% 33,097 SH Aug. 8, 2026 Daily
IBBQ · Invesco Exchange-Traded Fund Trust … 0.16% 4,127 SH Aug. 8, 2026 Daily
DMXF · iShares Trust 0.16% 5,282 SH Aug. 8, 2026 Daily
EFG · iShares Trust 0.16% 93,941 SH Aug. 8, 2026 Daily
IEV · iShares Trust 0.13% 7,437 SH Aug. 8, 2026 Daily
JDOC · J.P. Morgan Exchange-Traded Fund Tr… 0.12% 523 NS April 30, 2026 N-PORT
IEUR · iShares Trust 0.11% 33,776 SH Aug. 8, 2026 Daily
VGK · VANGUARD INTERNATIONAL EQUITY INDEX… 0.10% 143,256 SH Aug. 8, 2026 Daily
APIE · Trust for Professional Managers 0.09% 35,164 NS May 31, 2026 N-PORT
BIB · ProShares Trust 0.09% 2,379 NS May 31, 2026 N-PORT
AVDE · AMERICAN CENTURY ETF TRUST 0.08% 512,663 NS May 31, 2026 N-PORT
EFAV · iShares Trust 0.08% 14,760 SH Aug. 8, 2026 Daily
EFA · iShares Trust 0.08% 210,590 SH Aug. 8, 2026 Daily
IVLU · iShares Trust 0.08% 11,952 SH Aug. 8, 2026 Daily
IEFA · iShares Trust 0.07% 457,025 SH Aug. 8, 2026 Daily
IDEV · iShares Trust 0.06% 65,210 SH Aug. 8, 2026 Daily
PABD · iShares Trust 0.05% 614 SH Aug. 8, 2026 Daily
VEA · VANGUARD TAX-MANAGED FUNDS 0.05% 582,477 SH Aug. 8, 2026 Daily
VSGX · VANGUARD WORLD FUND 0.05% 12,034 SH Aug. 8, 2026 Daily
AVSD · AMERICAN CENTURY ETF TRUST 0.05% 8,646 NS May 31, 2026 N-PORT
ACWX · iShares Trust 0.05% 19,221 SH Aug. 8, 2026 Daily
PXF · Invesco Exchange-Traded Fund Trust … 0.04% 4,101 SH Aug. 8, 2026 Daily
IXUS · iShares Trust 0.04% 85,131 SH Aug. 8, 2026 Daily
VXUS · VANGUARD STAR FUNDS 0.04% 879,132 SH Aug. 8, 2026 Daily
VEU · VANGUARD INTERNATIONAL EQUITY INDEX… 0.04% 139,469 SH Aug. 8, 2026 Daily
INTF · iShares Trust 0.03% 3,699 SH Aug. 8, 2026 Daily
AVIV · AMERICAN CENTURY ETF TRUST 0.03% 17,483 NS May 31, 2026 N-PORT
URTH · iShares, Inc. 0.02% 5,529 SH Aug. 8, 2026 Daily
TOK · iShares Trust 0.02% 170 SH Aug. 8, 2026 Daily
ACWI · iShares Trust 0.02% 20,298 SH Aug. 8, 2026 Daily
IMFL · Invesco Exchange-Traded Self-Indexe… 0.01% 432 SH Aug. 8, 2026 Daily
VT · VANGUARD INTERNATIONAL EQUITY INDEX… 0.01% 52,382 SH Aug. 8, 2026 Daily
ONEQ · Fidelity Commonwealth Trust 0.01% 25,967 NS May 31, 2026 N-PORT
DFAI · Dimensional ETF Trust 0.00% 15,280 NS April 30, 2026 N-PORT
DFIV · Dimensional ETF Trust 0.00% 9,780 NS April 30, 2026 N-PORT
DFIC · Dimensional ETF Trust 0.00% 1,800 NS April 30, 2026 N-PORT
DFAX · Dimensional ETF Trust 0.00% 1,020 NS April 30, 2026 N-PORT
FTLS · First Trust Exchange-Traded Fund III -0.04% -36,345 NS April 30, 2026 N-PORT